Shots:

• Daiichi Sankyo to receive $1.35B upfront- $5.55B as regulatory & commercial milestones making the total deal value $6.9B. AstraZeneca to get WW co-development and co-commercialization rights for Daiichi’s trastuzumab deruxtecan (Ex- Japan) with equal cost & profit sharing
• The focus of the collaboration is to develop trastuzumab deruxtecan for HER2+ breast and gastric cancer with the expansion of AstraZeneca’s Oncology portfolio
• Trastuzumab deruxtecan (DS-8201) is ADC designed to deliver CT to cancer cells and has received FDA’s BT designation & MHLW’s Sakigake designation for HER2+ advanced or m-breast cancer & HER2-positive advanced gastric or gastroesophageal junction respectively with its expected FDA filling in Q2’19

   Ref: AstraZeneca | Image: AstraZeneca